Circulating miRNA-155 as a Potential Biomarker for Coronary Slow Flow
Table 3
Baseline laboratory characteristics of the study participants.
Variable
Control group ()
CSF group ()
value
WBC (109/L)
5.9 ± 1.2
6.1 ± 1.3
0.3601
Blood glucose
10.42 ± 0.63
10.57 ± 0.58
0.1571
HDL-C (mmol/L)
1.12 ± 0.25
1.18 ± 0.28
0.1964
LDL-C (mmol/L)
2.63 ± 0.73
2.53 ± 0.65
0.4074
TG (mmol/L)
1.48 ± 1.12
1.46 ± 1.16
0.9199
TC (mmol/L)
4.21 ± 0.68
4.24 ± 0.72
0.8060
Serum creatinine (umol/L)
58.62 ± 12.36
58.73 ± 11.43
0.9577
Cystatin C (mg/L)
0.92 ± 0.25
0.87 ± 0.28
0.2812
hs-CRP (mg/L)
1.91 ± 0.61
3.01 ± 1.16
<0.001
miRNA-155
0.09 ± 0.05
0.23 ± 0.09
<0.001
Variables measured with number of patients (percentages in parentheses or mean ± SD). CSF: coronary slow flow; WBC: white blood cells; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglyceride; TC: total cholesterol; hs-CRP: high-sensitivity C-reactive protein.
